keyword
MENU ▼
Read by QxMD icon Read
search

Cutaneous lymphomas

keyword
https://www.readbyqxmd.com/read/29783811/-cutaneous-extranodal-nasal-nk-t-cell-lymphoma-presenting-with-hemophagocytic-syndrome-in-pregnancy-report-of-a-case
#1
J H Chen, T T Wang, J Sun, X Y Lyu
No abstract text is available yet for this article.
May 8, 2018: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29779332/-primary-cutaneous-follicle-center-cell-lymphoma-a-case-report-and-literatures-review
#2
J Qiao, R N Lu, L Wang, M Y Song, Z Wang, Z H Zhang, J Y Li, W Xu
No abstract text is available yet for this article.
April 14, 2018: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
https://www.readbyqxmd.com/read/29779211/cutaneous-sarcoidosis-a-new-subset-in-the-spectrum-of-paraneoplastic-dermatoses
#3
M El-Khalawany, A Mosbeh, S Aboeldahab, S Ali
BACKGROUND: Sarcoidosis is a well-described disease that can be associated with various malignancies; however, this correlation is still not fully clarified. AIM: To determine the clinical and histological features, demographic characteristics, and prognosis of patients diagnosed with paraneoplastic sarcoidosis (PS). METHODS: This observational cohort prospective study included all patients diagnosed as cutaneous sarcoidosis. All patients were monitored for therapeutic response, prognosis, and any associated diseases or malignancies...
May 20, 2018: Clinical and Experimental Dermatology
https://www.readbyqxmd.com/read/29778492/tanovea%C3%A2-for-the-treatment-of-lymphoma-in-dogs
#4
REVIEW
Erik De Clercq
Tanovea® (first named GS-9219, then VDC-1101, generic name: rabacfosadine) is a pro-prodrug or "double" prodrug of PMEG [9-(2-phosphonylmethoxyethyl)guanine], which has been conditionally approved by the US FDA (Food and Drug Administration) for the treatment of lymphoma in dogs. Tanovea has been demonstrated to be effective against non-Hodgkin's lymphoma (NHL) in dogs, as well as canine cutaneous T-cell lymphoma, spontaneous canine multiple myeloma, naïve canine multicentric lymphoma and relapsed canine B-cell lymphoma...
May 17, 2018: Biochemical Pharmacology
https://www.readbyqxmd.com/read/29775497/inflammatory-cytokines-and-peripheral-mediators-in-the-pathophysiology-of-pruritus-in-cutaneous-t-cell-lymphoma
#5
REVIEW
Daniel J Lewis, Simo Huang, Madeleine Duvic
Cutaneous T-cell lymphoma (CTCL) includes a diverse group of neoplasms, including mycosis fungoides and Sézary syndrome. One of the earliest and most common symptoms of CTCL is pruritus, which affects up to 88% of patients. The severity of pruritus can range from mild to very debilitating, producing tremendous discomfort and a significant decrease in quality of life. Patients with advanced disease, in particular, may experience a more chronic, intractable pruritus. However, the underlying mechanism of pruritus in CTCL remains unknown...
May 18, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29773281/-cutaneous-and-systemic-t-cell-lymphoma-treated-with-haploidentical-bone-marrow-transplantation
#6
M Méchineaud, M Mercier, Y Le Corre, A Croué, N Ifrah, L Martin
BACKGROUND: Herein, we report a case of systemic cutaneous T-cell lymphoma refractory to standard therapy, the course of which resulted in haplo-identical bone marrow grafting. PATIENTS AND METHODS: A 53-year-old woman consulted for facial erythema with infiltration, keratotic lesions on the trunk, and adenopathies measuring around 1cm on the axilla and inguinal folds. A diagnosis was made of Sézary syndrome (SS), a leukaemic form of epidermotropic cutaneous T-cell lymphoma...
May 14, 2018: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29772037/a-review-of-fabry-disease
#7
A Cinats, E Heck
The class of medications known as Janus kinase inhibitors block cytokine-mediated signaling via the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, which plays an important role in immunoregulation and normal cell growth. This class includes the drugs tofacitinib, approved for the treatment of rheumatoid arthritis, and ruxolitinib, approved for the treatment of myelofibrosis and polycythemia rubra vera. The most common adverse events (AEs) reported in patients taking tofacitinib are infections, whereas the most common AEs in patients taking ruxolitinib are anemia and thrombocytopenia...
May 2018: Skin Therapy Letter
https://www.readbyqxmd.com/read/29766412/cutaneous-large-b-cell-lymphoma-involving-the-duodenum-and-the-bile-duct-a-case-report
#8
Lamine Hamzaoui, Mouna Medhioub, Amal Khsiba, Moufida Mahmoudi, Talel Badri, Mohamed Msaddak Azouz
No abstract text is available yet for this article.
May 16, 2018: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/29765972/reflectance-confocal-microscopy-as-new-diagnostic-tool-in-folliculotropic-mycosis-fungoides
#9
Gabriella Fabbrocini, Caterina Mazzella, Mariateresa Cantelli, Antonello Baldo, Daniela Russo, Gaetano De Rosa, Giuseppe Monfrecola
We present a case of folliculotropic mycosis fungoides (FMF), a variant of cutaneous T-cell lymphoma which particularly affects hair follicles. FMF can imitate a wide variety of otherwise benign dermatoses, so it poses major diagnostic obstacles both for the dermatologist as well as the dermatopathologist. In our case, in vivo reflectance confocal microscopy (RCM) was very important for guiding the skin biopsy site selection. For this reason, RCM can reduce the number of unsuccessful histopathological examinations and increase the diagnostic accuracy for different skin dermatoses...
April 2018: Skin Appendage Disorders
https://www.readbyqxmd.com/read/29764863/extracorporeal-photochemotherapy-drives-monocyte-to-dendritic-cell-maturation-to-induce-anti-cancer-immunity
#10
Alessandra Ventura, Aaron Vassall, Eve Robinson, Renata Filler, Douglas Hanlon, Katrina Meeth, Harib Ezaldein, Michael Girardi, Olga Sobolev, Marcus W Bosenberg, Richard L Edelson
Extracorporeal photochemotherapy (ECP) is a cancer immunotherapy for cutaneous T cell lymphoma (CTCL) operative in more than 350 centers worldwide. While its efficacy and favorable safety profile have driven its widespread use, elucidation of its underlying mechanism has been difficult. In this study, we identify the principal contributors to the anti-cancer immunotherapeutic effects of ECP, with the goal of enhancing potency and broadening applicability to additional malignancies. First, we scaled down the clinical ECP leukocyte-processing device to mouse size...
May 15, 2018: Cancer Research
https://www.readbyqxmd.com/read/29758280/multi-kinase-inhibitor-with-anti-p38%C3%AE-activity-in-cutaneous-t-cell-lymphoma
#11
Xu Hannah Zhang, Sangkil Nam, Jun Wu, Chih-Hong Chen, Xuxiang Liu, Hongzhi Li, Timothy McKeithan, Qiang Gong, Wing C Chan, Hongwei Holly Yin, Yate-Ching Yuan, Raju Pillai, Christiane Querfeld, David Horne, Yuan Chen, Steven T Rosen
Current cutaneous T cell lymphoma (CTCL) therapies are marked by an abbreviated response, subsequent drug resistance, and poor prognosis for patients with advanced disease. An understanding of molecular regulators involved in CTCL is needed to develop effective targeted therapies. One candidate regulator is p38γ, a mitogen-activated protein kinase crucial for malignant T cell activity and growth. p38γ gene expression is selectively increased in CTCL patient samples as well as cell lines, but not in healthy T cells...
May 11, 2018: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/29751499/survival-and-prognostic-factors-in-mixed-cryoglobulinemia-data-from-246-cases
#12
Cesare Mazzaro, Luigino Dal Maso, Endri Mauro, Valter Gattei, Michela Ghersetti, Pietro Bulian, Giulia Moratelli, Gabriele Grassi, Francesca Zorat, Gabriele Pozzato
INTRODUCTION: The clinical and therapeutic management of mixed cryoglobulinemia (MC) remains a subject of controversy. In addition, most studies have not recorded the long-term follow-up and the outcome of these cases. MATERIAL AND METHODS: We enrolled 246 patients affected by MC who were consecutively admitted to our Department from January 1993 to February 2013. Clinical and biological data had been recorded until June 2014. RESULTS: The median age (at diagnosis) was 60 years (range 26⁻83)...
May 3, 2018: Diseases (Basel)
https://www.readbyqxmd.com/read/29751003/special-at-rich-binding1-protein-satb1-in-malignant-t-cells
#13
Simon Fredholm, Andreas Willerslev-Olsen, Özcan Met, Linda Kubat, Maria Gluud, Sarah L Mathiasen, Christina Friese, Edda Blümel, David L Petersen, Tengpeng Hu, Claudia Nastasi, Lise M Lindahl, Terkild B Buus, Thorbjørn Krejsgaard, Mariusz A Wasik, Katharina L Kopp, Sergei B Koralov, Jenny L Persson, Charlotte M Bonefeld, Carsten Geisler, Anders Woetmann, Lars Iversen, Jurgen C Becker, Niels Odum
Deficient expression of Suppressor Special AT-rich Binding-1 (SATB1) hampers thymocyte development and results in inept T cell lineages. Recent data implicate dysregulated SATB1 expression in the pathogenesis of mycosis fungoides (MF), the most frequent variant of cutaneous T cell lymphoma (CTCL). Here we report on a disease-stage-associated decrease of SATB1 expression and an inverse expression of STAT5 and SATB1 in situ. Importantly, STAT5 inhibited SATB1 expression through induction of miR-155. Decreased SATB1 expression triggered enhanced expression of IL-5 and IL-9 (but not IL-6 and IL-32) whereas increased SATB1 expression had the opposite effect indicating that the mir-155 target SATB1 is a repressor of IL-5 and IL-9 in malignant T cells...
May 8, 2018: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/29745269/biophysical-and-photobiological-basics-of-water-filtered-infrared-a-hyperthermia-of-superficial-tumors
#14
Peter Vaupel, Helmut Piazena, Werner Müller, Markus Notter
Thermography-controlled, water-filtered infrared-A (wIRA) is a novel, effective and approved heating technique listed in the ESHO quality assurance guidelines for superficial hyperthermia clinical trials (2017). In order to assess the special features and the potential of wIRA-hyperthermia (wIRA-HT), detailed and updated information about its physical and photobiological background is presented. wIRA allows for (a) application of high irradiances without skin pain and acute grade 2-4 skin toxicities, (b) prolonged, therapeutically relevant exposure times using high irradiances (150-200 mW/cm2 ) and (c) faster and deeper heat extension within tissues...
May 10, 2018: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/29743350/high-throughput-sequencing-of-the-t-cell-receptor-%C3%AE-gene-identifies-aggressive-early-stage-mycosis-fungoides
#15
Adele de Masson, John T O'Malley, Christopher P Elco, Sarah S Garcia, Sherrie J Divito, Elizabeth L Lowry, Marianne Tawa, David C Fisher, Phillip M Devlin, Jessica E Teague, Nicole R Leboeuf, Ilan R Kirsch, Harlan Robins, Rachael A Clark, Thomas S Kupper
Mycosis fungoides (MF), the most common cutaneous T cell lymphoma (CTCL) is a malignancy of skin-tropic memory T cells. Most MF cases present as early stage (stage I A/B, limited to the skin), and these patients typically have a chronic, indolent clinical course. However, a small subset of early-stage cases develop progressive and fatal disease. Because outcomes can be so different, early identification of this high-risk population is an urgent unmet clinical need. We evaluated the use of next-generation high-throughput DNA sequencing of the T cell receptor β gene ( TCRB ) in lesional skin biopsies to predict progression and survival in a discovery cohort of 208 patients with CTCL (177 with MF) from a 15-year longitudinal observational clinical study...
May 9, 2018: Science Translational Medicine
https://www.readbyqxmd.com/read/29742194/widespread-skin-necrosis-secondary-to-gemcitabine-therapy
#16
Patrick M Zito, Adrianna M Gonzalez, Joshua D Fox, Megan Cronin, Nicholas Mackrides, Robert S Kirsner, Anna J Nichols
Gemcitabine, a pyrimidine nucleoside analogue, is an oncologic agent used in the treatment of cutaneous T-cell lymphoma (CTCL). Common dermatologic reactions associated with gemcitabine include alopecia, mild skin rash, and mucositis but skin necrosis is exceptional. Herein we present an unusual case of widespread skin necrosis mimicking toxic epidermal necrolysis in a 45-year-old woman receiving gemcitabine therapy for stage IIIA cutaneous T-cell lymphoma. This is the first reported case of a TEN-like reaction subsequent to gemcitabine treatment...
May 1, 2018: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/29741263/the-2017-who-update-on-mature-t-and-natural-killer-nk-cell-neoplasms
#17
REVIEW
E Matutes
Over the last decade, there has been a significant body of information regarding the biology of the lymphoid neoplasms. This clearly supports the need for updating the 2008 WHO (World Health Organization) classification of haematopoietic and lymphoid tumours. The 2017 WHO classification is not a new edition but an update and revision of the 4th edition. New provisional entities but not new definitive entities are included, and novel molecular data in most of the entities and changes in the nomenclature in few of them have been incorporated...
May 2018: International Journal of Laboratory Hematology
https://www.readbyqxmd.com/read/29740949/68-year-old-woman-with-multiple-sclerosis-cutaneous-t-cell-lymphoma-and-seizures
#18
Alireza Shams, Katherine Schwetye
No abstract text is available yet for this article.
May 2018: Brain Pathology
https://www.readbyqxmd.com/read/29734473/treatment-for-hepatitis-c-virus-associated-mixed-cryoglobulinaemia
#19
REVIEW
Nuria Montero, Alexandre Favà, Eva Rodriguez, Clara Barrios, Josep M Cruzado, Julio Pascual, Maria Jose Soler
BACKGROUND: Hepatitis C virus (HCV)-associated mixed cryoglobulinaemia is the manifestation of an inflammation of small and medium-sized vessels produced by a pathogenic IgM with rheumatoid factor activity generated by an expansion of B-cells. The immune complexes formed precipitate mainly in the skin, joints, kidneys or peripheral nerve fibres. Current therapeutic approaches are aimed at elimination of HCV infection, removal of cryoglobulins and also of the B-cell clonal expansions. The optimal treatment for it has not been established...
May 7, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29733229/healthcare-resource-utilization-costs-of-care-and-treatment-of-mycosis-fungoides-cutaneous-t-cell-lymphoma-patterns-in-a-large-managed-care-population-a-retrospective-us-claims-based-analysis
#20
Yuen Tsang, Tao Gu, Gaurav Sharma, Susan Raspa, Bill Drake, Hiangkiat Tan
PURPOSE: To evaluate health care utilization, treatment patterns and costs among patients with mycosis fungoides-cutaneous T-cell lymphoma (MF-CTCL). METHODS: This retrospective cohort study queried the HealthCore Integrated Research Database to identify patients ≥18 years with ≥2 diagnoses of MF-CTCL (ICD-9-CM code 202.1x, 202.2x) between 07 January 2006 and 07 January 2013. Index date was defined as first MF-CTCL diagnosis. Patients were continuously enrolled ≥6 months before and ≥12 months after index date...
May 7, 2018: Journal of Dermatological Treatment
keyword
keyword
52154
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"